Real-World Evidence Studies Demonstrate Improved Outcomes

College of Pharmacy and Hope Center investigator, Ivo Abraham, PhD, RN, co-authored two studies recently published in BMC Nephrology and Future Oncology. The first study, titled Potential Life-Years Gained Over a 5-Year Period by Correcting Dopps-Identified Modifable Practices in Haemodialysis: Results from the European Monitor CKD5 Study was a prospective, observational study on treatment outcomes of renal anemia management. By correcting six different modifiable hemodialysis practices, researchers estimated a 6.% increase in 5-year survival.

The second study, titled Chemotherapy-Induced Neutropenia/Febrile Neatropenia Prophylaxis with Biosimilar Filgastrim in Solid Tumors Versus Hematological Malignancies: MONITOR-GCSF Study collected real-world data from over 1400 patients. The study supported that adequate GCSF support in hematology to correct for current deficiencies would help to prevent hospializations and chemotherapy distrubances.